Anifrolumab therapy in Dermatomyositis: new insights from refractory patients.

Authors

Linda Carli, Lorenzo Cavagna, Chiara Cardelli, Federico Fattorini, Clelia Zampaglione, Michele Diomedi, Elenia Laurino, Marta Mosca

Published in

The Journal of rheumatology. Nov 01, 2025. Epub Nov 01, 2025.

Abstract

To analyse the efficacy and safety of anifrolumab, a monoclonal antibody addressed against the type I interferon receptor sub-unit 1, as a therapeutic option in patients with a refractory cutaneous dermatomyositis (DM).
Patients with DM presenting a cutaneous involvement refractory to different immunosuppressive treatments were enrolled. The Cutaneous Disease Area activity (CDASI-a) was used to evaluate the evolution of skin involvement; moreover, also manual muscle test 8 (MMT8) and patient global assessment (PGA) were collected, to evaluate both muscle involvement and patients' quality of life. Finally, we also registered the changes in glucocorticoid (GC) daily dose, to explore the possible steroid sparing effect of the drug.
We enrolled 4 patients (2 women, mean age 60 years). At the enrollment, they showed an active cutaneous disease (mean CDASI-a 27/100); the mean MMT8 value was 67.5/80; their mean daily dose of GC was 10 mg of prednisolone (PDN) and their mean value of PGA was 7.5/10. After treatment, all these parameters were improved, with a CDASI value decreased to 8.75/100, an MMT8 increased to 71.3/80, a daily dose of GC decreased to 4 mg and a PGA decreased to 1.5/10.
The data we collected showed a significant reduction in CDASI-a values; furthermore, our results showed an improvement also in muscle involvement and in patients' perception of the disease's burden. Finally, a steroid sparing effect and a globally good safety profile of anifrolumab were observed, thus confirming anifrolumab as a new valid therapeutic option in this kind of patients.

PMID:
41176342
Bibliographic data and abstract were imported from PubMed on 02 Nov 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.